Supha Pharmachem (BOM:539561) Cyclically Adjusted Revenue per Share: ₹11.58 (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:539561 Supha Pharmachem Ltd BOM:539561
54 GF Score
Price ₹0.29
GF Value ₹1.51
Valuation Possible Value Trap
! 12 Warning Signs
View Full Analysis

What is Supha Pharmachem Cyclically Adjusted Revenue per Share?

Supha Pharmachem BOM:539561 -3.33% 54 Cyclically Adjusted Revenue per Share is ₹11.58 as of Sep. 2025. GuruFocus rates BOM:539561 with a GF Score™ of 54/100 and a GF Value™ of ₹1.51 (Possible Value Trap). The stock has 12 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Supha Pharmachem's adjusted revenue per share for the three months ended in Sep. 2025 was ₹1.288. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹11.58 for the trailing ten years ended in Sep. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-26), Supha Pharmachem's current stock price is ₹0.29. Supha Pharmachem's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2025 was ₹11.58. Supha Pharmachem's Cyclically Adjusted PS Ratio of today is 0.03.

During the past 11 years, the highest Cyclically Adjusted PS Ratio of Supha Pharmachem was 0.39. The lowest was 0.02. And the median was 0.10.


Supha Pharmachem  (BOM:539561) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Supha Pharmachem's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.29/11.58
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 11 years, the highest Cyclically Adjusted PS Ratio of Supha Pharmachem was 0.39. The lowest was 0.02. And the median was 0.10.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Supha Pharmachem Cyclically Adjusted Revenue per Share Related Terms


Supha Pharmachem Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Supha Pharmachem's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Supha Pharmachem Cyclically Adjusted Revenue per Share Chart

Supha Pharmachem Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 10.98

Supha Pharmachem Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 10.77 10.98 11.27 11.58

BOM:539561 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Supha Pharmachem's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Supha Pharmachem Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Supha Pharmachem's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Supha Pharmachem's Cyclically Adjusted PS Ratio falls into.


BOM:539561
54GF Score
Supha Pharmachem Ltd BOM:539561
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Supha Pharmachem Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Supha Pharmachem's adjusted Revenue per Share data for the three months ended in Sep. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Sep. 2025 (Change)*Current CPI (Sep. 2025)
=1.288/162.2892*162.2892
=1.288

Current CPI (Sep. 2025) = 162.2892.

Supha Pharmachem Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201512 0.024 102.901 0.038
201603 0.035 102.518 0.055
201606 0.006 105.961 0.009
201609 0.003 105.961 0.005
201612 0.002 105.196 0.003
201703 0.011 105.196 0.017
201706 0.001 107.109 0.002
201709 0.002 109.021 0.003
201712 0.001 109.404 0.001
201803 0.002 109.786 0.003
201806 0.000 111.317 0.000
201809 0.000 115.142 0.000
201812 0.000 115.142 0.000
201903 0.002 118.202 0.003
201906 0.003 120.880 0.004
201909 0.023 123.175 0.030
201912 0.011 126.235 0.014
202003 0.013 124.705 0.017
202006 0.004 127.000 0.005
202009 0.355 130.118 0.443
202012 0.233 130.889 0.289
202103 0.967 131.771 1.191
202106 2.400 134.084 2.905
202109 2.081 135.847 2.486
202112 3.571 138.161 4.195
202203 0.696 138.822 0.814
202206 1.719 142.347 1.960
202209 2.743 144.661 3.077
202212 3.057 145.763 3.404
202303 1.309 146.865 1.446
202306 5.721 150.280 6.178
202309 8.112 151.492 8.690
202312 31.752 152.924 33.696
202403 24.383 153.035 25.858
202406 1.326 155.789 1.381
202409 0.395 157.882 0.406
202412 0.697 158.323 0.714
202503 5.122 157.552 5.276
202506 1.219 159.755 1.238
202509 1.288 162.289 1.288

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹11.58 mean?
Supha Pharmachem (BOM:539561) has a Cyclically Adjusted Revenue per Share of ₹11.58 as of Sep. 2025. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Supha Pharmachem and its competitors.
Is Supha Pharmachem's Cyclically Adjusted Revenue per Share too high?
Supha Pharmachem's current Cyclically Adjusted Revenue per Share is ₹11.58. Overall, Supha Pharmachem has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Supha Pharmachem's Cyclically Adjusted Revenue per Share compare to ZTS?
Supha Pharmachem's Cyclically Adjusted Revenue per Share of ₹11.58 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Supha Pharmachem and its competitors. Supha Pharmachem's current Cyclically Adjusted Revenue per Share is ₹11.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Supha Pharmachem stock overvalued right now?
Based on GuruFocus' analysis, Supha Pharmachem (BOM:539561) is currently considered Possible Value Trap. The stock's GF Value™ is ₹1.51, compared to a current price of ₹0.29 — trading 80.8% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹11.58. Supha Pharmachem's overall GF Score™ is 54/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Supha Pharmachem (BOM:539561), the current Cyclically Adjusted Revenue per Share is ₹11.58 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Supha Pharmachem (BOM:539561) Overvalued in 2026?

Based on GuruFocus' analysis, Supha Pharmachem stock appears to be undervalued. The current stock price of ₹0.29 is trading 80.8% below its estimated GF Value™ of ₹1.51. GuruFocus considers Supha Pharmachem to be Possible Value Trap.

Key valuation signals for BOM:539561:

  • Cyclically Adjusted Revenue per Share: ₹11.58
  • GF Value™: ₹1.51 vs. price of ₹0.29 (80.8% below fair value)
  • GF Score™: 54/100 with 12 warning signs

No single metric tells the full story. See the BOM:539561 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Supha Pharmachem Business Description

Address Saugbaug Road, Office No. 9, Behind Ravi Vihar Hotel, K Raheja Prime, Marol Industrial Estate, Andheri (East), Mumbai, MH, IND, 400059
Supha Pharmachem Ltd, formerly known as Remedium Lifecare Ltd, is engaged in the business of trading in API Intermediates (KSMs & CRMs) and various other raw materials used in API trading viz. Iso propyl Alcohol (IPA), Cyclohexane, DI Iso Propyl Amine (DIPA), Ethyl Acetate, Hydrazine Hydrate, Iso propyl Alcohol (IPA), Methylene Di Chloride, Potassium Carbonate Powder, Sodium Bi-Carbonate, Potassium Hydroxide Flakes, Sodium Chloride (Common Salt), Sodium Carbonate (SODA ASH), Amino isophthalic Acid, Tellurium(IV) Oxide, Grignard Reagent, Iodine, Selenium Metal Powder, Trimethyl Sulfoxonium Iodide (TMSI).
54GF Score

Get the complete analysis for BOM:539561

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹0.29
Price
₹1.51
GF Value